TG Therapeutics (NASDAQ:TGTX) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

TG Therapeutics (NASDAQ:TGTX) announced its quarterly earnings data on Monday. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01), Briefing.com reports. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The business had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. During the same period in the prior year, the company earned $0.73 EPS. The company’s revenue was down 49.4% on a year-over-year basis.

TG Therapeutics Trading Up 1.0 %

NASDAQ:TGTX traded up $0.28 during mid-day trading on Thursday, reaching $27.45. The company’s stock had a trading volume of 468,810 shares, compared to its average volume of 3,636,246. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83. The stock has a market cap of $4.25 billion, a P/E ratio of -271.70 and a beta of 2.19. The company’s fifty day simple moving average is $23.65 and its two-hundred day simple moving average is $20.30. TG Therapeutics has a twelve month low of $9.81 and a twelve month high of $27.80.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. TD Cowen began coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 target price for the company. HC Wainwright increased their target price on TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday. The Goldman Sachs Group upped their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday. Finally, B. Riley lifted their price objective on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $37.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.